Contineum Launches IPO Campaign to Accelerate Multiple Sclerosis Pipeline

1. Contineum Therapeutics announced IPO plans on March 18, 2024, aiming to raise funds for the advancement of their Multiple Sclerosis (MS) drug pipeline.
2. The biotech company intends to allocate part of the IPO proceeds towards completing a Phase II trial for PIPE-307, a drug candidate covered by the agreement with Johnson & Johnson (J&J).
3. Contineum filed an SEC document on March 17, 2024, marking its entry into the 2024 IPO class.
4. The specific amount raised during the IPO event is not mentioned in the provided sources; however, it is noted that Contineum priced its IPO, which suggests a successful fundraising effort.